JP2013523705A5 - - Google Patents

Download PDF

Info

Publication number
JP2013523705A5
JP2013523705A5 JP2013501932A JP2013501932A JP2013523705A5 JP 2013523705 A5 JP2013523705 A5 JP 2013523705A5 JP 2013501932 A JP2013501932 A JP 2013501932A JP 2013501932 A JP2013501932 A JP 2013501932A JP 2013523705 A5 JP2013523705 A5 JP 2013523705A5
Authority
JP
Japan
Prior art keywords
ester
physiologically acceptable
formula
acceptable salt
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013501932A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013523705A (ja
JP6023696B2 (ja
Filing date
Publication date
Priority claimed from GBGB1005518.4A external-priority patent/GB201005518D0/en
Priority claimed from GBGB1005522.6A external-priority patent/GB201005522D0/en
Application filed filed Critical
Priority claimed from PCT/GB2011/000497 external-priority patent/WO2011121305A2/en
Publication of JP2013523705A publication Critical patent/JP2013523705A/ja
Publication of JP2013523705A5 publication Critical patent/JP2013523705A5/ja
Application granted granted Critical
Publication of JP6023696B2 publication Critical patent/JP6023696B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013501932A 2010-03-31 2011-03-31 ミョウバンアジュバントおよびミョウバンアジュバント化ワクチンの保存方法 Active JP6023696B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1005518.4A GB201005518D0 (en) 2010-03-31 2010-03-31 Preservation of alum-adjuvanted vaccines
GB1005522.6 2010-03-31
GBGB1005522.6A GB201005522D0 (en) 2010-03-31 2010-03-31 Method for preserving alum-adjuvanted vaccines
GB1005518.4 2010-03-31
PCT/GB2011/000497 WO2011121305A2 (en) 2010-03-31 2011-03-31 Method for preserving alum adjuvants and alum-adjuvanted vaccines

Publications (3)

Publication Number Publication Date
JP2013523705A JP2013523705A (ja) 2013-06-17
JP2013523705A5 true JP2013523705A5 (enExample) 2014-04-24
JP6023696B2 JP6023696B2 (ja) 2016-11-09

Family

ID=43971221

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013501932A Active JP6023696B2 (ja) 2010-03-31 2011-03-31 ミョウバンアジュバントおよびミョウバンアジュバント化ワクチンの保存方法

Country Status (13)

Country Link
US (1) US9101607B2 (enExample)
EP (1) EP2552410B1 (enExample)
JP (1) JP6023696B2 (enExample)
KR (1) KR101819250B1 (enExample)
CN (1) CN102892409B (enExample)
AU (1) AU2011234268B2 (enExample)
BR (1) BR112012025044A2 (enExample)
CA (1) CA2795050C (enExample)
DK (1) DK2552410T3 (enExample)
ES (1) ES2708989T3 (enExample)
GB (1) GB2499480A (enExample)
HU (1) HUE042330T2 (enExample)
WO (1) WO2011121305A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5869553B2 (ja) 2010-03-31 2016-02-24 スタビリテック リミテッド ウイルス粒子、ポリペプチド又は生体材料を安定化させる添加剤
JP5960120B2 (ja) 2010-03-31 2016-08-02 スタビリテック リミテッド ウイルス粒子の安定化
GB201117233D0 (en) 2011-10-05 2011-11-16 Stabilitech Ltd Stabilisation of polypeptides
GB201406569D0 (en) * 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
US9588123B2 (en) * 2014-04-11 2017-03-07 Surmodics Ivd, Inc. Compositions and methods for in vitro diagnostic tests including zwitterionic solubilization reagent
GB2562241B (en) * 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
AR111760A1 (es) * 2017-05-19 2019-08-14 Novartis Ag Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
CN113750228B (zh) * 2021-09-25 2024-02-20 大连理工大学 一种冷冻保护剂在铝佐剂中的应用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3927208A (en) 1973-05-14 1975-12-16 Rit Rech Ind Therapeut Live bovine adenovirus vaccines, preparation thereof and method of vaccination using them
US4631189A (en) 1980-03-10 1986-12-23 Da Vinci Laboratories, a division of FoodScience Corporation N,N-dimethylglycine and use in immune response
JPS6013718A (ja) 1983-07-05 1985-01-24 Chemo Sero Therapeut Res Inst B型肝炎ワクチン
JPS60193925A (ja) 1984-03-13 1985-10-02 Chemo Sero Therapeut Res Inst 凍結乾燥製剤化ワクチン
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
JPS61189228A (ja) 1985-02-19 1986-08-22 Nippon Sekijiyuujishiya 血液凝固第8因子製剤の製法
US4950596A (en) 1985-03-04 1990-08-21 The Dow Chemical Company Stabilization of intracellular enzymes
JPS6238173A (ja) 1985-08-13 1987-02-19 三菱レイヨン株式会社 抗血液凝固剤
US5169758A (en) 1986-05-02 1992-12-08 Boehringer Mannheim Gmbh Stabilized, NAD(P)H-dependent, soluble nitrate reductase, a process for the preparation thereof and a reagent containing it
NZ221306A (en) 1986-08-15 1990-02-26 Commw Scient Ind Res Org 2-component immunoadjuvant comprising a mycobacterial free immunoadjuvant oil and a polycationic polyelectrolyte immunoadjuvant and vaccines thereof
ATE82506T1 (de) * 1987-08-21 1992-12-15 Imcera Group Inc Stabilisierung von wachstumshormonen.
GB8826429D0 (en) 1988-11-11 1988-12-14 Univ Leeds Ind Service Ltd Enzyme stabilisation systems
CA2065023A1 (en) 1989-08-15 1991-02-16 Brent Dorval Stabilized vaccine compositions
AU650045B2 (en) 1990-09-12 1994-06-09 Lifecell Corporation Method and apparatus for cryopreparation dry stabilization and rehydration of biological suspensions
ZA936095B (en) 1992-08-21 1994-03-14 Univ Melbourne Cytokine applications.
AU5543294A (en) 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
GB9521806D0 (en) 1995-10-25 1996-01-03 Cortecs Ltd Preservation methods
FR2746109B1 (fr) 1996-03-12 1998-04-17 Rhone Poulenc Rorer Sa Milieu pour la conservation de materiel biologique
CA2242035C (en) 1997-07-01 2004-11-23 Transgene S.A. Compositions useful for transferring therapeutically active substances into a target cell, and their use in gene therapy
KR20010032550A (ko) 1997-11-26 2001-04-25 유니버설 프리저베이션 테크놀로지스 인코포레이티드 유리화에 의한 민감한 생물학적 시료의 보존방법
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
ES2323991T3 (es) 1998-11-16 2009-07-28 Introgen Therapeutics, Inc. Formulacion de adenovirus para terapia genica.
AUPQ347199A0 (en) 1999-10-15 1999-11-11 Csl Limited Novel polypeptide fragments
KR20030020294A (ko) * 2000-06-08 2003-03-08 파우더젝트 백신, 인코포레이티드 분말 조성물
DE10041515A1 (de) 2000-08-24 2002-03-14 Gerold Schuler Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen
US20040110267A1 (en) 2000-12-15 2004-06-10 Stratagene Room temperature stable competent cells
EP1399131A2 (en) 2001-06-08 2004-03-24 Powderject Vaccines, Inc. Spray freeze-dried compositions
US7101693B2 (en) 2001-09-07 2006-09-05 Brigham Young University Plasticized hydrophilic glasses for improved stabilization of biological agents
JP4936618B2 (ja) 2001-09-21 2012-05-23 株式会社ノエビア 微細エマルション組成物
US20040161776A1 (en) * 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
EP1946776B1 (en) 2002-02-27 2017-01-18 Immunex Corporation Stabilized tnfr-fc composition comprising arginine
WO2004002534A1 (en) 2002-06-27 2004-01-08 Novo Nordisk A/S Use of dimethyl sulfone as isotonicity agent
CA2491805A1 (en) 2002-07-10 2004-01-22 Transgene S.A. Modified adenoviral fiber with ablated binding to cellular receptors
AU2003272174A1 (en) 2002-10-21 2004-05-04 Biotage Ab Use of osmolytes to heat stabilise luciferase and/or apyrase
JP2006521084A (ja) 2002-12-10 2006-09-21 シェーリング−プラウ・リミテッド イヌranklならびにイヌranklを調製および使用するための方法
US20060247167A1 (en) 2003-09-01 2006-11-02 Novo Nordisk A/S Stable formulations of peptides
US7642077B2 (en) 2003-12-08 2010-01-05 Genencor International, Inc. Biocomposite comprising co-precipitate of enzyme, silicate and polyamine
WO2005062709A2 (en) 2003-12-30 2005-07-14 Virumar Pituach Tarkivim Ltd. Integrated viral complexes, methods of production thereof, vaccines containing same and methods of use thereof
SG150570A1 (en) 2004-03-03 2009-03-30 Revance Therapeutics Inc Compositions and methods for topical diagnostic and therapeutic transport
US20060058238A1 (en) 2004-09-15 2006-03-16 Lee Laurent-Applegate Fetal skin cell protein compositions for the treatment of skin conditions, disorders or diseases and methods of making and using the same
EP3173072A1 (en) 2004-10-01 2017-05-31 Ramscor, Inc. Conveniently implantable sustained release drug compositions
KR20070107079A (ko) 2005-01-28 2007-11-06 와이어쓰 안정화된 액체 폴리펩타이드 제형
GB0502661D0 (en) 2005-02-09 2005-03-16 Stabilitech Ltd A desiccated product
TWI398272B (zh) 2005-03-08 2013-06-11 Intervet Int Bv 化學定義的安定劑
KR20150032915A (ko) 2005-04-08 2015-03-30 아르고스 쎄라퓨틱스 인코포레이티드 수지상 세포 조성물 및 방법
EP1933867A1 (en) 2005-10-04 2008-06-25 Alk-Abello A/S Solid vaccine formulation
JP5138601B2 (ja) 2005-11-21 2013-02-06 サノフィ パストゥール リミテッド 組換えウイルス安定化製剤
ES2352855T3 (es) 2005-11-30 2011-02-23 International Institute Of Cancer Immunology, Inc. Nuevos compuestos peptídicos del tumor de wilms.
WO2008051245A2 (en) 2005-12-02 2008-05-02 Novartis Ag Nanoparticles for use in immunogenic compositions
EP1987067A4 (en) * 2006-02-15 2012-01-25 Imclone Llc ANTIBODY FORMULATION
ES2286951B1 (es) * 2006-05-26 2008-10-01 Instituto Cientifico Y Tecnologico De Navarra, S.A Nanoparticulas bioadhesivas para la administracion de moleculas biologicamente activas.
CA2668417A1 (en) 2006-11-03 2008-05-15 Alphavax, Inc. Alphavirus and alphavirus replicon particle formulations and methods
GB0705245D0 (en) 2007-03-19 2007-04-25 Stabilitech Ltd Stable biological products
EP2829282B1 (en) * 2007-03-22 2017-10-25 The Regents of The University of Colorado, A Body Corporate Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
EP2150537A4 (en) * 2007-06-01 2010-09-22 Acologix Inc STABLE PEPTIDE FORMULATION AT HIGH TEMPERATURE
EP2192908A4 (en) * 2007-07-25 2010-09-01 Bioe Inc DIFFERENTIATION OF PRECURSOR CELLS OF MULTIPLE ABSTRACTS AGAINST CHONDROCYTES
US20090123436A1 (en) 2007-11-08 2009-05-14 Surmodics, Inc. Cryopreservative compositions and methods
JP2012503637A (ja) 2008-09-24 2012-02-09 スタビリテック リミテッド 糖およびポリエチレンイミンを使用するポリペプチドの保存方法
US20110212127A1 (en) 2008-09-24 2011-09-01 Stabilitech Ltd. Method for Preserving Polypeptides Using a Sugar and Polyethyleneimine
CN101670104A (zh) 2009-09-24 2010-03-17 浙江大学 一种含人参皂甙的油佐剂及其制备方法
JP5960120B2 (ja) 2010-03-31 2016-08-02 スタビリテック リミテッド ウイルス粒子の安定化

Similar Documents

Publication Publication Date Title
JP2013523704A5 (enExample)
DOP2012000300A (es) Activadores de guanilato ciclase soluble
EA201400679A1 (ru) Композиция сухого порошка производного азола для ингаляции
PE20140845A1 (es) Formulaciones parenterales de vacunas contra los norovirus
JP2013523676A5 (enExample)
RU2015118581A (ru) Лиофилизированные препараты мелфалана флуфенамида
Newcomer et al. Approved and experimental countermeasures against pestiviral diseases: bovine viral diarrhea, classical swine fever and border disease
CN106063933B (zh) 通用疫苗冻干保护剂及其应用
NZ630219A (en) Lyophilization of synthetic liposomal pulmonary surfactant
JP2013542263A5 (enExample)
AR090592A1 (es) Sales de 5-[(1r)-2-({2-[4-(2,2-difluoro-2-feniletoxi)fenil]etil}amino)-1-hidroxietil]-8-hidroxiquinolin-2(1h)-ona
JP6023696B2 (ja) ミョウバンアジュバントおよびミョウバンアジュバント化ワクチンの保存方法
JP2016506905A5 (enExample)
PE20100365A1 (es) Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion
AR088907A1 (es) Vacuna
RU2016136327A (ru) Композиции на основе мелатонина для парентерального введения
JP6235614B2 (ja) 注射用hpph凍結乾燥粉末注射剤およびその製造方法
JP2016534062A5 (enExample)
RU2013157188A (ru) Композиции св-183,315 и относящиеся к ним способы
RU2016101248A (ru) Лиофилизированные препараты бендамустина гидрохлорида
RU2017135950A (ru) Композиции для лечения фиброза и связанных с фиброзом состояний
Asim et al. Effect of various stabilizers on titre of lyophilized live-attenuated Peste des petits ruminants (PPR) vaccine.
RU2016115374A (ru) Фармацевтические композиции, содержащие антибактериальные агенты
JP2017517574A5 (enExample)
JP2013543881A5 (enExample)